Drug resistance is the main reason HIV patients have trouble with their medications failing, doctors say, but a local laboratory is breaking ground on a new class of therapeutics called fusion inhibitors, which may attack resistant HIV strains.
Panacos Pharmaceuticals Inc. ? a Gaithersburg biotechnology company developing antiviral therapeutics ? presented its HIV fusion inhibitor program at the XVI International AIDS Conference in Toronto this week.
Recommended Stories
Print subscriber? Click here to login/register your account
Digital subscriber? Click here to login/register your account.